www.mnk.com
Open in
urlscan Pro
146.214.96.202
Public Scan
Submitted URL: http://www.mnk.com/
Effective URL: https://www.mnk.com/
Submission: On June 09 via manual from PH — Scanned from DE
Effective URL: https://www.mnk.com/
Submission: On June 09 via manual from PH — Scanned from DE
Form analysis
1 forms found in the DOMGET /SearchBlock/Search
<form action="/SearchBlock/Search" method="get"> <input type="hidden" name="redirect" value="/corporate-search-results/">
<input type="hidden" name="section" value="CorporateContent">
<input name="searchText" type="search" placeholder="Search">
<button type="submit">
<i class="fa fa-search"></i>
</button>
</form>
Text Content
Search Font Size * About Us * About Us Back About Us * Executive Committee Back Executive Committee * Sigurdur (Siggi) Olafsson * Jason Goodson * Lisa French * Kassie Harrold * Henriette Nielsen * Bryan Reasons * Dr. Peter Richardson * Mark Tyndall * Stephen Welch * Select Senior Leaders Back Select Senior Leaders * Daniel Speciale * Board of Directors Back Board of Directors * Paul Bisaro * Sigurdur (Siggi) Olafsson * Daniel Celentano * Riad El-Dada * Neal Goldman * Karen Ling * Dr. Woodrow (Woody) Myers * Susan Silbermann * James Sulat * Scientific Advisory Council * Specialty Generics * COVID-19 * Blog * Core Strengths * Diversity, Equity and Inclusion * MNK Recent Acquisitions * Our Story * Partnering Back Partnering * Suppliers * Patient Stories * 155th Anniversary * Products * Research * Research Back Research * Science & Technology Back Science & Technology * Pipeline * Research & Development Back Research & Development * Clinical Trials * Formulation & Drug Delivery Technologies * Medical Affairs Back Medical Affairs * Research Studies - IIR/ECR * Research & Educational Grants * Responsibility * Responsibility Back Responsibility * Community Outreach Back Community Outreach * Mallinckrodt Community Giving * Philanthropy Contacts * Corporate Compliance * Expanded Access Program for Investigational Products * Interactions with Health Care Professionals * Our Product Pricing * Quality, Environment, Health & Safety * Sustainability * Corporate Social Responsibility * Investor Relations * Contact Us * News & Media * Careers * Careers Back Careers * Who We Are * What We Do * Our Values & People * Where We Are * Search All Opportunities Mallinckrodt uses cookies to improve and analyze site functionality. Some aspects of the site may not function properly without cookies enabled. To learn more about how we use cookies and how you can change your cookies settings, please read our Privacy Policy. By continuing to browse the site, you are agreeing to accept our use of cookies. I Agree SEEING COMPLEXITY IN A NEW LIGHT Where others see complexity, we see value for patients and shareholders SEEING VALUE FOR PATIENTS Where others see complexity, we see healthier lives SEEING OPPORTUNITY FOR SHAREHOLDERS Where others see complexity, we see potential for growth MANAGING COMPLEXITY. IMPROVING LIVES. For more than 150 years, Mallinckrodt has been advancing the fields of science and medicine to improve the lives of people around the world. About Us BOLD PATH. BRIGHTER FUTURE. Grow your career, and become part of our legacy as we make a lasting difference in the lives of patients. Careers A DIVERSE AND GROWING PIPELINE. Mallinckrodt is focused on developing innovative therapies and cutting-edge technologies for patients with severe and critical conditions and has products spanning all phases of clinical development. Pipeline MANAGING COMPLEXITY. IMPROVING LIVES. NEWS & MEDIA Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023 Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023 Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023 Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023 SUCCESSFUL COMPLETION OF FINANCIAL REORGANIZATION Go to mnk.com/corporatefactsheet to learn more about Mallinckrodt and our path forward. Read More 2020 CORPORATE SOCIAL RESPONSIBILITY REPORT RELEASED Mallinckrodt releases its 2020 Corporate Social Responsibility Report highlighting our continued commitment and ongoing progress. Read More INCLUSION & DIVERSITY We are strengthened by the value we derive from the varied identities, experiences, cultures and views of our employees. Our Commitment OUR PRODUCT PRICING Our goal is to price our products responsibly while providing the best possible healthcare for the greatest number of people. Product Pricing OUR PRODUCTS Building on our heritage and distinctive capabilities, our world-class development and formulation expertise bring medical solutions to the marketplace. Get Product Information Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.© 2021 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland. UnitedHealthcare creates and publishes the Machine-Readable Files on behalf of Mallinckrodt. To link to the Machine-Readable Files, please click on the URL provided: transparency-in-coverage.uhc.com. RESOURCES FOR: * Career Seekers * Investors * Suppliers ABOUT MALLINCKRODT: * About Us * Home * Investor Relations * News & Media * Products * Research * Responsibility OTHER LINKS: * Calif. Supply Chain Disclosure * Contact Us * Patents * Privacy Policy * Safety Data Sheets * Terms of Use * UK Modern Slavery Act Disclosure * UHC Transparency in Coverage * C-TPAT Statement of Support